The market is suffering from a 'three-body problem,' says BTIG's Jonathan Krinsky
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
24/7 Wall St. on MSN3d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
bovnews2d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Nasdaq5d
BTIG sees Uber Q4 bookings more in middle than high-end of outlook
BTIG analyst Jake Fuller says that while Uber‘s (UBER) commentary on its U.S. rideshare business “felt constructive” at intra-quarter appearances, the firm’s receipt data was “more ...
Traders Magazine9y
BTIG Expands Transition Management, Hires Howell to Boost Business
BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is ...
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
Glaukos price target raised to $157 from $149 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...
GeneDx management to meet with BTIG
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
Investing11d
BTIG sees a risk for 'a bigger January decline' in S&P 500
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...